Abcam plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABCM research report →
Companywww.abcam.com
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies.
- CEO
- Alan Thomas Hirzel BS,
- IPO
- 2020
- Employees
- 1,760
- HQ
- Cambridge, GB
Price Chart
Valuation
- Market Cap
- $5.52B
- P/E
- 578.45
- P/S
- 0.00
- P/B
- 3.88
- EV/EBITDA
- 2.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 71.21%
- Op Margin
- 2.03%
- Net Margin
- 1.40%
- ROE
- 0.76%
- ROIC
- 0.65%
Growth & Income
- Revenue
- $361.70M · -43.19%
- Net Income
- $-8,500,000 · -135.93%
- EPS
- $-0.04 · -135.26%
- Op Income
- $-10,200,000
- FCF YoY
- -118.55%
Performance & Tape
- 52W High
- $25.32
- 52W Low
- $12.48
- 50D MA
- $23.15
- 200D MA
- $19.98
- Beta
- 0.86
- Avg Volume
- 5.82M
Get TickerSpark's AI analysis on ABCM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ABCM Coverage
We haven't published any research on ABCM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABCM Report →